<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[efficacy Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/efficacy.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to efficacy]]></description>
	<s:counts start="0" returned="20" found="91" />
	<language>en-us</language>
	<item>
		<title><![CDATA[ZymoGenetics, Inc., Q1 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-295855.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator Instructions Your first question comes from Edward Tenthoff from Piper Jaffray. Edward Tenthoff - Piper Jaffray First Doug, just back from [eosol], definitely pleased to see the great efficacy with Interferon lambda and that uniqe mechanism starting to bear out.  I was intrigued by...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 05 May 2009 17:42:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[Efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+bancorp+piper+jaffray+inc..html"><![CDATA[U.S. Bancorp Piper Jaffray Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/zymogenetics+inc..html"><![CDATA[ZymoGenetics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ZGEN</category>
		<category domain="tickers">ZGEN</category>
	</item>
	<item>
		<title><![CDATA[Is EQ a Placebo?]]></title>
		<link><![CDATA[http://blogs.bnetau.com.au/aussierules/2009/03/09/is-eq-a-placebo/]]></link>
		<description><![CDATA[On 23/2/09 Denise Mannix posted the following on this blog.    Hi Chris    I know you do not appear to be too partial to the Mayer-Salovey work on emotions. I would suggest that if you haven't already undertaken the individual MSCEIT and had the feedback...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 09 Mar 2009 23:01:05 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[Efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/work.html"><![CDATA[Work]]></category>
		<category domain="http://resources.bnet.com/topic/accuracy.html"><![CDATA[Accuracy]]></category>
		<category domain="http://resources.bnet.com/topic/emotional+intelligence.html"><![CDATA[Emotional Intelligence]]></category>
		<category domain="http://resources.bnet.com/topic/leadership.html"><![CDATA[Leadership]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[Productivity]]></category>
		<category domain="http://resources.bnet.com/topic/tools+%2526+techniques.html"><![CDATA[Tools & Techniques]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/chris+golis.html"><![CDATA[Chris Golis]]></category>
		<category domain="http://resources.bnet.com/topic/chris+golis.html"><![CDATA[Chris Golis]]></category>
	</item>
	<item>
		<title><![CDATA[Array BioPharma F1Q09 (Qtr End 09/30/08) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-246344.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you, sir.  Operator Instructions.  We&#8217;ll take our first question from Jim Birchenough with Barkley&#8217;s Capital.   Jim Birchenough &#8211; Barclays Capital  Hi guys, congratulations on the progress this year.   Bob Conway  Thank you.   Jim Birchenough &#8211; Barclays...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 04 Nov 2008 09:51:07 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/compound.html"><![CDATA[Compound]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[Efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/compound.html"><![CDATA[Compound]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[Efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/array+biopharma+inc..html"><![CDATA[Array BioPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARRY</category>
		<category domain="tickers">ARRY</category>
	</item>
	<item>
		<title><![CDATA[Allergan Inc. F3Q08 (Qtr End 9/30/08) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-244934.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you.  Operator Instructions.  Our first question is from Ronny Gal of Bernstein Research. Ronny Gal Hi, good morning guys.  First, David, are we okay in assuming that the bottom of that guidance range for '09 assume kind of early approval for Roloxin and...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 29 Oct 2008 14:36:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[Efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[Efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_27/ai_n30935676]]></link>
		<description><![CDATA[Anti-cancer compound exhibits significant efficacy and toxicity values leading to further development  PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the results of its anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. "I am encouraged by the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 27 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[RegeneRx Sponsors "Walk a Mile in My Shoes" for National Epidermolysis Bullosa Awareness Week]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_24/ai_n30932989]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is a major sponsor of "Walk a Mile in My Shoes," the signature event of National Epidermolysis Bullosa EB Awareness Week. The "Walk a Mile in My Shoes" program coordinates events that include rallies, meetings and walk-a-thons in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 24 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/regenerx+biopharmaceuticals+inc..html"><![CDATA[RegeneRX Biopharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/wound.html"><![CDATA[wound]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RGN</category>
		<category domain="tickers">RGN</category>
	</item>
	<item>
		<title><![CDATA[RegeneRx President and CEO to Speak at 7th Annual BIO Investor Forum]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_22/ai_n30918250]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 22 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/regenerx+biopharmaceuticals+inc..html"><![CDATA[RegeneRX Biopharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RGN</category>
		<category domain="tickers">RGN</category>
	</item>
	<item>
		<title><![CDATA[Upstream Biosciences&#39; Potential Tropical Disease Treatments Demonstrate Promising Signs of Efficacy at McGill University]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200810/ai_n29490294]]></link>
		<description><![CDATA[Upstream Biosciences Inc. (OTCBB: UPBS) today announced that its second generation of novel antiparasitic agents demonstrated in vitro efficacy against both Leishmaniasis and Trypanosomiasis. Upstream's novel compounds were tested by Dr. Armando Jardim at the Institute of Parasitology of McGill University in Montreal, Quebec, Canada. Upstream continues to collaborate with...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 07 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cad.html"><![CDATA[CAD]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/mcgill+university.html"><![CDATA[McGill University]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[RegeneRx to Develop RGN-457 for Cystic Fibrosis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Oct_1/ai_n29469728]]></link>
		<description><![CDATA[RegeneRx Seeking Strategic Partnership to Address CF in U.S. and Europe  BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis CF. RGN-457 is based on thymosin beta 4...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Oct 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/regenerx+biopharmaceuticals+inc..html"><![CDATA[RegeneRX Biopharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RGN</category>
		<category domain="tickers">RGN</category>
	</item>
	<item>
		<title><![CDATA[RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_20/ai_n28012561]]></link>
		<description><![CDATA[BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company's topical drug candidate, RGN-137, in seventy-two patients with pressure...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 20 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Titan Pharmaceuticals Announces SpheramineŽ Presentations at 12th International Congress of Parkinson's Disease and Movement Disorders]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_24/ai_n27506127]]></link>
		<description><![CDATA[Five-Year Update of Pilot Study Shows Spheramine Reduces Severity and Frequency of Parkinson's Symptoms While Also Improving Health-Related Quality of Life  CHICAGO & SOUTH SAN FRANCISCO -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Spheramine[R], the company's novel cell-based therapy being developed in collaboration with Bayer Schering Pharma AG...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 24 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[cell]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/parkinson.html"><![CDATA[Parkinson]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/titan+pharmaceuticals+inc..html"><![CDATA[Titan Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">TTP</category>
		<category domain="tickers">TTP</category>
	</item>
	<item>
		<title><![CDATA[SPEEDEL REPORTS ON DATA PUBLISHED AT HYPERTENSION 2008 MEDICAL CONGRESS]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n27511158]]></link>
		<description><![CDATA[Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presented at Hypertension 2008, the joint meeting of the International Society of Hypertension ISH and the European Society of Hypertension ESH in Berlin (14- 19 June 2008). Results from the Phase IIa proof-of-concept...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 19 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bp+plc.html"><![CDATA[BP Plc]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Cleveland BioLabs to Submit Protectan CBLB502 for BARDA BAA for Development of Therapies to Protect Civilian Population From Radiation Exposure]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200804/ai_n25136538]]></link>
		<description><![CDATA[Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will submit Protectan CBLB502 for the Broad Agency Announcement BAA soliciting research and development proposals for "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation" published on March 6, by the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 09 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/radiation.html"><![CDATA[radiation]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+health+and+human+services.html"><![CDATA[U.S. Department of Health and Human Services]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Healthcare Stocks to Watch: HSXI, HEPH, OPXA, WPI.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200803/ai_n25262978]]></link>
		<description><![CDATA[M2 PRESSWIRE-12 March 2008-Financialbusinessnews.us: Healthcare  Stocks to Watch: HSXI, HEPH, OPXA, WPIC1994-2008 M2 COMMUNICATIONS LTD    RDATE:12032008    Boston, MA -- HealthSonix, Inc. (OTC: HSXI); Hollis-Eden  Pharmaceuticals, Inc. (NASDAQ: HEPH); Opexa Therapeutics, Inc. (NASDAQ:  OPXA); Watson Pharmaceuticals, Inc. (NYSE: WPI)   ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/opexa+therapeutics+inc..html"><![CDATA[Opexa Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/watson+pharmaceuticals+inc..html"><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">OPXA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WPI</category>
		<category domain="tickers">NDAQ,OPXA,WPI</category>
	</item>
	<item>
		<title><![CDATA[PURE Bioscience Announces Licensing and Distribution Agreement with Mid-Continent Packaging, Inc. for SDC-based Private Label Hard Surface Disinfectant]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_6/ai_n24376723]]></link>
		<description><![CDATA[Biosilver[TM] Disinfectant Targeted to Direct-to-Consumer Television Shopping Networks  SAN DIEGO -- PURE Bioscience (OTCBB: PURE) today announced it has granted a license to privately held Mid-Continent Packaging, Inc., a company with over 45 years experience in contract chemical packaging, for blending, packaging and distribution of PURE's patented silver dihydrogen...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 06 Mar 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/brand.html"><![CDATA[brand]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[MARKETING]]></category>
		<category domain="http://resources.bnet.com/topic/pure+bioscience.html"><![CDATA[PURE Bioscience]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+environmental+protection+agency.html"><![CDATA[U.S. Environmental Protection Agency]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PURE</category>
		<category domain="tickers">PURE</category>
	</item>
	<item>
		<title><![CDATA[Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200801/ai_n23682528]]></link>
		<description><![CDATA[CALGARY, Canada, January 7 /PRNewswire/ --     Oncolytics Biotech  Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported  today  that a research group led by Dr. Richard Vile of the Mayo Clinic  College of Medicine in Rochester, Minnesota, published the results of  its ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 07 Jan 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/dr..html"><![CDATA[Dr.]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/fax.html"><![CDATA[Fax]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/mayo+clinic.html"><![CDATA[Mayo Clinic]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Cleveland BioLabs Not Selected for Defense Contract Award]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200801/ai_n21184117]]></link>
		<description><![CDATA[Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it was informed by the Department of Defense DoD that Protectan CBLB502, the Company's candidate for the treatment of gastrointestinal GI effects of acute radiation syndrome was not selected for award under the request for proposal RFP No. W9113M-07-R-0002, entitled, "Medical Radiation...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 04 Jan 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/radiation.html"><![CDATA[radiation]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+defense.html"><![CDATA[U.S. Department of Defense]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Lunchtime Investor Focus.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200801/ai_n25237915]]></link>
		<description><![CDATA[M2 PRESSWIRE-4 January 2008-Businessnetwire.us: Lunchtime Investor  FocusC1994-2008 M2 COMMUNICATIONS LTD     RDATE:04012008     New York, NY -- BusinessNetWire's "Investor's  Update" Focuses on the Following Companies:     Wellco Energy Services Trust (TSX: WLL.UN); Paladin Labs Inc. (TSX:  PLB); Cleveland...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 04 Jan 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/compound.html"><![CDATA[compound]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+defense.html"><![CDATA[U.S. Department of Defense]]></category>
		<category domain="http://resources.bnet.com/topic/webcast.html"><![CDATA[Webcast]]></category>
		<category domain="http://resources.bnet.com/topic/women.html"><![CDATA[women]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[DYNETICS AWARDED CONTRACT FOR SYNERGISTIC ELECTRONICS WARFARE]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5561/is_200712/ai_n22710397]]></link>
		<description><![CDATA[Dynetics, Incorporated of Huntsville, Ala., is being awarded a contract for $24,000,000. This action provides for Synergistic Electronics Warfare Program renamed Multi-Yield RFCM Investing and Development to develop advanced Electronic Warfare techniques and technologies that extended USAF radio frequency battle-space access against advanced Integrated Air Defense System and the asymmetrical...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 20 Dec 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/air+force.html"><![CDATA[Air Force]]></category>
		<category domain="http://resources.bnet.com/topic/alabama.html"><![CDATA[Alabama]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[PRODUCTIVITY]]></category>
		<category domain="http://resources.bnet.com/topic/technique.html"><![CDATA[technique]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[USA: DYNETICS AWARDED CONTRACT FOR SYNERGISTIC ELECTRONICS WARFARE.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6465/is_200712/ai_n25740895]]></link>
		<description><![CDATA[Dynetics, Incorporated of Huntsville, Ala., is being awarded a  contract for $24,000,000. This action provides for Synergistic  Electronics Warfare Program renamed Multi-Yield RFCM Investing and  Development to develop advanced Electronic Warfare techniques and  technologies that extended USAF radio frequency battle-space access  against advanced Integrated Air...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 20 Dec 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/air+force.html"><![CDATA[Air Force]]></category>
		<category domain="http://resources.bnet.com/topic/alabama.html"><![CDATA[Alabama]]></category>
		<category domain="http://resources.bnet.com/topic/efficacy.html"><![CDATA[efficacy]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/productivity.html"><![CDATA[PRODUCTIVITY]]></category>
		<category domain="http://resources.bnet.com/topic/radar.html"><![CDATA[radar]]></category>
		<category domain="http://resources.bnet.com/topic/technique.html"><![CDATA[technique]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
